OSE IMMUNOTHERAPE.EO -20
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II c… Read more
Market Cap & Net Worth: OSE IMMUNOTHERAPE.EO -20 (6OP)
OSE IMMUNOTHERAPE.EO -20 (F:6OP) has a market capitalization of $83.77 Million (€81.61 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #20439 globally and #2203 in its home market, demonstrating a -5.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OSE IMMUNOTHERAPE.EO -20's stock price €3.64 by its total outstanding shares 22420176 (22.42 Million).
OSE IMMUNOTHERAPE.EO -20 Market Cap History: 2015 to 2026
OSE IMMUNOTHERAPE.EO -20's market capitalization history from 2015 to 2026. Data shows change from $192.97 Million to $83.77 Million (-8.20% CAGR).
OSE IMMUNOTHERAPE.EO -20 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OSE IMMUNOTHERAPE.EO -20's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6OP by Market Capitalization
Companies near OSE IMMUNOTHERAPE.EO -20 in the global market cap rankings as of March 18, 2026.
Key companies related to OSE IMMUNOTHERAPE.EO -20 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
OSE IMMUNOTHERAPE.EO -20 Historical Marketcap From 2015 to 2026
Between 2015 and today, OSE IMMUNOTHERAPE.EO -20's market cap moved from $192.97 Million to $ 83.77 Million, with a yearly change of -8.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €83.77 Million | -30.53% |
| 2025 | €120.59 Million | -27.32% |
| 2024 | €165.93 Million | +68.46% |
| 2023 | €98.50 Million | -35.00% |
| 2022 | €151.55 Million | -36.19% |
| 2021 | €237.50 Million | +49.57% |
| 2020 | €158.79 Million | +90.61% |
| 2019 | €83.31 Million | +11.04% |
| 2018 | €75.02 Million | -11.80% |
| 2017 | €85.06 Million | -46.47% |
| 2016 | €158.91 Million | -17.65% |
| 2015 | €192.97 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of OSE IMMUNOTHERAPE.EO -20 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $83.77 Million USD |
| MoneyControl | $83.77 Million USD |
| MarketWatch | $83.77 Million USD |
| marketcap.company | $83.77 Million USD |
| Reuters | $83.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.